Seeking programs underserved by traditional VCs, MD Anderson launches fund to support trials

A new fund co-founded by MD Anderson is intended to support early development of a subset of drug candidates that are not served by traditional venture capital or biopharmas, but which the cancer research center believes should be evaluated.

MD Anderson and newly launched Focus Fund G.P. have raised more than $50 million toward Cancer Focus Fund L.P., a vehicle that will fund development of cancer therapeutics for which MD Anderson will also apply its clinical trial expertise. Investments are likely to stretch from late preclinical testing to Phase I and Phase Ib/II studies...